August 2012
-
According to the Hong Kong Department of Health (DH), Nycomed (Hong Kong) has voluntarily recalled a batch of Omnaris ciclesonide nasal spray due “a quality defect.” The product, from batch number 137930, was manufactured in… Read more . . .
-
Two Phase 3 studies to evaluate the safety of twice daily doses of a fixed dose combination dry powder formulation of aclidinium bromide and formoterol fumarate in 3,500 patients with moderate to severe COPD have… Read more . . .
-
Ampio Pharmaceuticals has announced results of a randomized, double-blinded study of its intranasal Ampion, a biologic anti-inflammatory, for the treatment of nasal inflammation. According to the company, Ampion “is naturally produced by humans in response… Read more . . .
-
The upcoming Aerosols–Inhalation and Nasal Drug Products Workshop sponsored by the United States Pharmacopoeia’s General Chapters-Dosage Forms Expert Committee will take place at USP headquarters in Rockville, MD on December 12 and 13, and the… Read more . . .
-
Mylan gets Pfizer’s respiratory delivery platform, acquires global rights to generic Diskus products
US generics company Mylan Inc. has obtained worldwide rights to develop, manufacture and commercialize Pfizer’s generic equivalent to GlaxoSmithKline’s Advair Diskus and Seretide Diskus products for asthma and COPD using Pfizer’s proprietary dry powder inhalation technology.… Read more . . .
-
Within the last week, Discovery Laboratories has announced that its aerosolized KL4 surfactant has received orphan drug designation from the EU for the treatment of cystic fibrosis, and it has presented data on a new… Read more . . .
-
Sunovion is presenting results from a 26-week double-blind, randomized Phase 3 study of ciclesonide HFA nasal aerosol involving more than 1,100 patients with perennial allergic rhinitis (PAR) that showed statistically significant improvement in nasal symptoms… Read more . . .
-
The 2011 Drug Delivery to the Lungs (DDL) Conference, which takes place December 7-9 in Edinburgh, UK, will highlight a particularly strong field of scientific presentations from both established industry experts and up-and-coming young researchers,… Read more . . .
-
CRO Catalent Pharma Solutions has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), a consortium of companies involved in the development, manufacture, and marketing of OINDPs, whose mission is “to advance scientifically… Read more . . .
-
US Senator Jim DeMint, a Republican from South Carolina, failed to persuade the US Senate to prohibit the use of tax dollars for enforcement of the FDA ban on the CFC-propelled OTC epinephrine inhaler Primatene… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland